Hai Robotics Joins the United Nations Global Compact
4.9.2023 06:01:00 EEST | Business Wire | Press release
Hai Robotics, a global leading provider of autonomous case-handling robots (ACR) systems, is proud to announce that it has joined the United Nations Global Compact initiative—the world's largest voluntary corporate sustainability initiative.
Hai Robotics joins thousands of organizations across 160 countries that are committed to taking responsible business action to build a more sustainable and inclusive society. Hai Robotics commits to uphold the Ten Principles of the UN Global Compact and support the UN in achieving the Sustainable Development Goals (SDG). Hai Robotics will also share an annual Communication on Progress to showcase its continued engagement.
"At Hai Robotics, we view sustainability as crucial in driving our long-term growth and resilience, and strive to serve as a responsible corporate citizen for our stakeholders," said Richie Chen, Founder and CEO at Hai Robotics. "We are excited to join the UN Global Compact in its mission to accelerate corporate sustainability. As a company continuing to expand globally, we recognize the growing importance of incorporating ESG increasingly into our business strategy. Participating in the UN Global Compact is critical in the improvement of our sustainability efforts during the development of warehouse automation solutions."
Hai Robotics is actively involved in reducing its environmental footprint through sustainable business practices and production methods. Hai Robotics implements action in sustainable sourcing to hold itself accountable across all stages of the supply chain, such as the use of composite wood in packaging. With this new commitment, Hai Robotics will evaluate its existing ESG activities and support for clients to ensure they align with UN's Sustainable Development Goals and create positive impact. For more information on Hai's ESG efforts and commitment, click here to access our annual sustainability report.
As the largest corporate sustainability initiative in the world, the UN Global Compact consists of more than 15,000 companies and 3,800 non-business signatories across over 160 countries, and more than 69 Local Networks. The Sustainable Development Goals consist of 17 global goals aimed to tackle societal issues and improve the quality of life by 2030, covering five key areas of people, planet, prosperity, peace and partnership.
About Hai Robotics
Hai Robotics, a leading global provider of Autonomous Case-handling Robot (ACR) systems, is committed to providing flexible, intelligent, and efficient warehouse automation solutions through robotics technology and AI algorithms. The HaiPick solution, independently developed in 2015, is the world's first ever ACR solution. Hai Robotics is a global enterprise that has more than 1,000 projects worldwide and serves customers from more than 30 countries and regions. We have offices to cover the United States, Europe, Japan, South Korea, Southeast Asia and Australia. We strive to combine global experience with local expertise to provide our customers with tailored, quality solutions. Hai Robotics is also a Participant of the United Nations Global Compact and adhere to its principles-based approach to responsible business. To learn more about Hai Robotics, visit www.hairobotics.com/
About the United Nations Global Compact
As a special initiative of the UN Secretary-General, the United Nations Global Compact is a call to companies everywhere to align their operations and strategies with Ten Principles in the areas of human rights, labour, environment and anti-corruption. Our ambition is to accelerate and scale the global collective impact of business by upholding the Ten Principles and delivering the Sustainable Development Goals through accountable companies and ecosystems that enable change. With more than 15,000 companies and 3,000 non-business signatories based in over 160 countries, and 69 Local Networks, the UN Global Compact is the world’s largest corporate sustainability initiative — one Global Compact uniting business for a better world. For more information, follow @globalcompact on social media and visit our website at unglobalcompact.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230903281684/en/
Contact information
Jennifer Kang
jennifer.kang@hairobotics.com
pr@hairobotics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom